Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12286233 | 0.80 | AKR1C3 (0.81) | AKR1C3AKR1C2PTGS1AKR1C4 | |
| SCHEMBL13802419 | 0.80 | AKR1C3 (0.58) | KMT2AKDM4EMEN1ABCB1AKR1C3 | |
| SCHEMBL4216463 | 0.80 | AKR1C3 (0.58) | KMT2AABCB1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL31432746 | 0.80 | CDC25A (0.55) | KDM4ELMNAMAPTHTTCDC25A | |
| SCHEMBL13813995 | 0.80 | KMT2A (0.66) | KMT2AKDM4EMEN1PTGS2LMNA | |
| SCHEMBL16072693 | 0.80 | KMT2A (0.58) | KMT2AKDM4EMEN1ABCB1PTGS2 | |
| SCHEMBL2467334 | 0.79 | CDC25A (0.54) | KDM4EAKR1C3AKR1C2LMNACDC25A | |
| SCHEMBL28466412 | 0.78 | KMT2A (0.61) | KMT2AKDM4EMEN1AKR1C3AKR1C2 | |
| SCHEMBL27474952 | 0.78 | AKR1C3 (0.59) | KMT2AKDM4EABCB1AKR1C3AKR1C2 | |
| SCHEMBL9153676 | 0.78 | AKR1C3 (0.50) | KMT2AKDM4EABCB1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | KMT2A 2408/4885KDM4E 4461/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.